Anti-htlv-1 drug and therapeutic agent for htlv-1-associated myelopathy/tropical spastic paraparesis (ham/tsp)
AssigneeKagoshima University
InventorsDaisuke KODAMA, Shuji IZUMO
Life of this patent
Estimating the term…
Abstract
A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.
Claims4
A therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), which comprises a substance selected from the group consisting of imatinib, nilotinib, and dasatinib as an active ingredient.
(canceled)
An anti-HTLV-1 drug, which comprises a substance selected from the group consisting of imatinib, nilotinib, and dasatinib as an active ingredient.
(canceled)
Dependencies are inferred from the claim text.